Standard BioTools Inc. filed an 8-K on November 19, 2026, reporting the results of a virtual special meeting at which stockholders approved all seven proposals related to its pending merger with Treeline Biosciences, Inc., including a share issuance, a reverse stock split, and a corporate name change.
Key Highlights
- Quorum reached: 281,744,412 votes, representing approximately 71.38% of total voting power, were present or represented by proxy at the Special Meeting.
- Share issuance approved: Stockholders voted 274,099,041 for and 7,571,806 against the issuance of Common Stock in connection with the Merger under Nasdaq Listing Rules 5635(a) and 5635(b).
- Name change and reverse split approved: The charter amendment to rename the company "Treeline Biosciences, Inc." and effect a reverse stock split at a ratio between 1-for-20 and 1-for-40 passed with 275,584,914 votes for and 6,123,396 against.
- Element Mass Cytometry Divestiture approved: The proposal, which may constitute a sale of substantially all company assets under Section 271 of the Delaware General Corporation Law, received 276,299,544 votes for and 5,336,020 against.
- Post-Closing equity plans approved: Both the Post-Closing Equity Incentive Plan (207,381,782 for) and the Post-Closing ESPP (224,903,287 for) were approved, each contingent on the closing of the Merger.
- Record date share count: As of October 16, 2026, there were 394,711,296 shares of Common Stock issued, outstanding, and entitled to vote.
Standard BioTools Special Meeting: All Seven Proposals Pass Ahead of Treeline Merger
Standard BioTools Inc. (NASDAQ:LAB) held a virtual special meeting of stockholders on November 19, 2026, to vote on proposals described in a definitive proxy statement/prospectus filed with the SEC on October 21, 2026, pursuant to Rule 424(b)(3), forming part of the company's registration statement on Form S-4 (File No. 333-297560), which the SEC declared effective on October 21, 2026. The record date for the meeting was October 16, 2026, at which time 394,711,296 shares of common stock, par value $0.001 per share, were issued and outstanding.
All seven proposals submitted to stockholders were approved. The Share Issuance Proposal, authorizing the issuance of Common Stock in connection with the Merger in accordance with Nasdaq Listing Rules, passed with 274,099,041 votes for. The Charter Amendment Proposal, which covers both a reverse stock split at a ratio mutually agreed by the company and Treeline Biosciences, Inc. in the range of 1-for-20 to 1-for-40, and a corporate name change to "Treeline Biosciences, Inc.," passed with 275,584,914 votes for. The Element Mass Cytometry Divestiture Proposal, noted in the filing as a transaction that may be considered a sale of substantially all of the assets of the company under Section 271 of the Delaware General Corporation Law, received 276,299,544 votes for. The filing noted there were no broker non-votes with respect to any of the proposals.
The Post-Closing Equity Incentive Plan and Post-Closing ESPP, both filed as exhibits 10.1 and 10.2 respectively, will become effective at the effective time of the Merger and are each contingent on the closing of the Merger, according to the filing. The nonbinding, advisory compensation proposal relating to Transaction-Related Compensation passed with 248,805,322 votes for. The company also issued a press release on November 19, 2026, announcing the stockholder vote results, furnished as Exhibit 99.1.
What Was Disclosed
Standard BioTools disclosed the final voting results from its November 19, 2026, special stockholder meeting, at which all seven proposals passed, including merger-related share issuance, a reverse stock split, a name change to Treeline Biosciences, Inc., and approval of two post-closing equity compensation plans.



Please wait processing your request...